The FDA has approved orforglipron, a once-daily oral GLP-1 receptor agonist, for adults with obesity, or with overweight plus at least one weight-related comorbidity. Eli Lilly will sell it as Foundayo.
What makes it different is not the indication — there are already GLP-1 drugs for this — but the molecule. Orforglipron is a small molecule, a synthetic chemical of the kind most pills are made of, rather than a peptide. Practically, that means it can be taken without restrictions on food or water.
The weight-loss numbers
The approval rests on the ATTAIN programme. In ATTAIN-1, at 72 weeks and using the efficacy estimand, adults lost 7.8% of body weight on 6 mg, 9.3% on 12 mg and 12.4% on 36 mg. The drug also lowered systolic blood pressure and improved triglycerides, non-HDL cholesterol, total cholesterol and LDL cholesterol.
One detail is worth flagging for anyone quoting the headline: 36 mg was the highest dose tested in the trial, while approved maintenance doses top out at 17.2 mg. The 12.4% belongs to a dose that is not on the label's ceiling.
Dosing and tolerability
The label starts at 0.8 mg, rising to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days or more. Further increases — to 9 mg, 14.5 mg or 17.2 mg — can follow at intervals of at least 30 days, depending on response and tolerability.
The most common adverse events in ATTAIN-1 were gastrointestinal and mild to moderate in severity. Serious adverse events were reported by 5.5% of those on 6 mg, 5.4% on 12 mg and 3.8% on 36 mg.
A 50-day approval
The regulatory timeline is its own data point. Orforglipron was approved under the FDA's Commissioner's National Priority Voucher pilot 50 days after filing — the fastest approval of a new molecular entity since 2002, according to the agency. The PDUFA date had been 20 January 2027.
It lands a little over three months after oral semaglutide 25 mg (Wegovy, Novo Nordisk) became the first oral GLP-1 approved for overweight or obesity, on 22 December.
Price and access
Lilly says Foundayo will be available from 6 April through LillyDirect, with retail pharmacies and telehealth clinics following. The lowest dose is $149 a month for patients paying cash, and Medicare Part D beneficiaries may be able to get it for as little as $50 a month from July.
Why the small molecule matters
Robert Dubin, of the Pennington Biomedical Research Center, makes the technical case in the accompanying commentary. Oral semaglutide is the same molecule as the injectable, with about 1% bioavailability; Novo added an absorption enhancer, salcaprozate sodium, to get it across. That enhancer can also increase absorption of other medicines taken at the same time — one study showed a 30% to 40% rise in thyroxine exposure when given with oral semaglutide. Orforglipron does not need the enhancer, and does not need fasting.
His practical point is not about Lilly versus Novo. It is that the constraint on obesity treatment has moved from the molecule to the logistics: primary care capacity, cost and access. Whether a pill beats an injection on adherence — currently dismal for injectables — is an open question, and the answer will matter more at population level than another percentage point of weight loss. Ninety percent of the value of this approval will be decided in clinics that have never prescribed a GLP-1 before, and in whether a cash price of $149 a month moves the people who need it most.